Evidence map›Paper›PMID 22124930›Full record

ArticleBiotechnology and bioengineering2012

A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors.

Nelita T Elliott, Fan Yuan

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017
    Review
  6. Article
  7. Article
  8. Organ-on-a-chip platforms for studying drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nelita T ElliottDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA.
Fan Yuan

Funding

Minority Predoctoral Fellowship ProgramF31CA123714 · NCI · DUKE UNIVERSITY · PI ELLIOTT, NELITA T · 2006 to 2009
$146k
NCI NIH HHS CA123714NCI NIH HHS F31 CA123714
6 · The paper itself

Abstract

Three-dimensional (3D) tumor models have been established in various microfluidic systems for drug delivery and resistance studies in vitro. However, one of the main drawbacks of these models is non-uniform distribution of cells, leaving regions with very low cell density within the 3D structures. As a result, molecular diffusion in the cell compartments is faster than that observed in solid tumors. To solve this problem, we developed a new technique for preparation of 3D tumor models in vitro. It was based on a microfluidic device containing three parallel channels separated by narrowly spaced posts. Tumor cells were loaded into the central channel at high density. To test the system, B16.F10 melanoma cells were perfusion-cultured overnight and the resulting 3D structure was characterized in terms of viability, density, and morphology of cells as well as transport properties of small fluorescent molecules. Immediately upon loading of tumor cells, the cell density was comparable to those observed in B16.F10 tumor tissues in vivo; and the viability of tumor cells was maintained through the overnight culture. The tumor model displayed low extracellular space and high resistance to diffusion of small molecules. For membrane-permeant molecules (e.g., Hoechst 33342), the rate of interstitial penetration was extremely slow, compared to membrane-impermeant molecules (e.g., sodium fluorescein). This versatile tumor model could be applied to in vitro studies of transport and cellular uptake of drugs and genes.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorMiceMicrofluidicsModels, TheoreticalOrgan Culture TechniquesPlasmacytomaAntineoplastic Agents

Identifiers

PMID22124930
PMCPMC4163945

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.